Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study

Rett syndrome is a rare, genetic neurodevelopmental disorder. Trofinetide is a synthetic analog of glycine–proline–glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome. In this phase 3 study (https...

Descripción completa

Detalles Bibliográficos
Autores principales: Neul, Jeffrey L., Percy, Alan K., Benke, Timothy A., Berry-Kravis, Elizabeth M., Glaze, Daniel G., Marsh, Eric D., Lin, Tim, Stankovic, Serge, Bishop, Kathie M., Youakim, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287558/
https://www.ncbi.nlm.nih.gov/pubmed/37291210
http://dx.doi.org/10.1038/s41591-023-02398-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287558/
https://www.ncbi.nlm.nih.gov/pubmed/37291210
http://dx.doi.org/10.1038/s41591-023-02398-1

Ejemplares similares